Ailani, Jessica
Andrews, Jeffrey Scott
Tockhorn-Heidenreich, Antje
Wenzel, Richard
Rettiganti, Mallikarjuna
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
https://doi.org/10.1007/s12325-022-02233-y
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
https://doi.org/10.1007/s12325-021-01911-7
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
https://doi.org/10.1007/s40261-021-01115-5
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 30 March 2022
Accepted: 17 June 2022
First Online: 5 August 2022